Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

This study has been terminated.
(Enrollment was far below anticipated participation and there is insufficient data to publish.)
Celgene Corporation
Information provided by (Responsible Party):
Duke University Identifier:
First received: September 10, 2010
Last updated: September 17, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2014
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)